Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model

Immunological Reviews

Volumn 184, Issue , 2001, Pages 236-243

  Kuppen, Peter J K ^a   Gorter, Arko ^a   Hagenaars, Martin ^a   Jonges, Liesbeth E ^a   Giezeman Smits, Katinka M ^a   Nagelkerke, J Fred ^b   Fleuren, Gertjan ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PHOSPHATASE; SCLEROPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL MODEL; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM METASTASIS; RATS;

EID: 0035704745     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065x.2001.1840121.x     Document Type: Review

References (81)

1. Cancer statistics, 2000
2. Tumour immunotherapy: The adjuvant treatment of the 21st century?
3. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas
4. Frequency of abnormal expression of HLA-A, B, C, and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence
5. The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells
6. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF)
7. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
8. Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin-2
9. Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2
10. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2
11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells
12. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells
13. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2
14. Regression of pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
15. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
16. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
17. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells
18. Accumulation of adaptively transferred adherent, lymphokine-activated killer cells in murine metastases
19. Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels
20. Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion
21. Tumor localization of adaptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
22. The microscopic anatomy of experimental rat CC531 colon tumour metastases: Consequences for immunotherapy?
23. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma
24. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration
25. The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adaptively transferred interleukin-2-activated natural killer cells in Wag rats
26. NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis
27. Characteristics of tumor infiltration by adoptively transferred and endogenous natural killer cells in a syngeneic rat model: Implications for the mechanism behind anti-tumor responses
28. Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model
29. Tissue distribution of adoptively transferred adherent LAK cells: Role of the route of administration
30. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells
31. Locoregional immunotherapy for nonresectable malignant hepatic disease
32. Regional adoptive immunotherapy with interleukin-2 and lymphokine- activated killer (LAK) cells for liver metastases
33. Treatment of unresectable hepatoma via selective hepatic artery infusion of lymphokine-activated killer cells generated from autologous spleen cells
34. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
35. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma
36. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity
37. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells
38. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: Implication for adoptive immunotherapy
39. The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats
40. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations
41. Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry
42. The phenotypic heterogeneity of human natural killer cells: Presence of at least 48 different subsets in the peripheral blood
43. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells
44. Rapid IL-2 induced adherence of human natural killer cells: Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells
45. Requirement for natural killer cells in the induction of cytotoxic T cells
46. Immune regulation: A critical link between NK cells and CTLs
47. Early appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes
48. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation
49. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer
50. Interleukin-2-activated natural killer cells can induce both apoptosis and necrosis in rat hepatocytes
51. Remodeling of the actin cytoskeleton of target hepatocytes and NK cells during induction of apoptosis
52. Induction of proliferation in vitro of resting human natural killer cells: Expression of surface activation antigens
53. + large granular lymphocytes in the induction of tumor necrosis factor by Mycobacterium avium-intracellulare complex
54. Ultrastructure of interactions between activated murine natural killer cells and melanoma cells in an extracellular matrix (Matrigel(R)) environment
55. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: Role of natural killer cells
56. The role of natural killer cells in immune surveillance of cancer
57. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum
58. FLT3-ligand administration inhibits liver metastases: Role of NK cells
59. - tumor cells
60. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells
61. Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations
62. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues
63. Lymphocytes stimulated with recombinant human interleukin 2: Relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice
64. Matrix metalloproteinases produced by rat IL-2-activated NK cells
65. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors
66. In search of the 'missing self': MHC molecules and NK cell recognition
67. Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells
68. Natural killer cell activation and inhibition by receptors for MHC class I
69. The origin and functions of natural killer cells
70. Human NK-cell receptors
71. Killer cell inhibitory receptors: Diversity, specificity, and function
72. NK cell receptors: Of missing sugar and missing self
73. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis
74. The regulatory role of CD45 on rat NK cells in target cell lysis
75. Characterization of three new membrane structures on rat NK cells which are involved in activation of the lyric machinery
76. Novel monoclonal antibodies against membrane structures that are preferentially expressed on IL-2-activated rat NK cells
77. The role of basement membrane in colorectal cancer invasion and liver metastasis
78. Distribution of individual components of basement membrane in human colon polyps and adenocarcinomas as revealed by monoclonal antibodies
79. Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation
80. Migration of IL-2 activated natural killer cells in vitro: Influence of extracellular matrix proteins
81. Migratory functions of natural killer cells